PhysioGenix Inc.
This article was originally published in Start Up
Executive Summary
PhysioGenix wants to reduce drug failure rates in clinical trials with multigenic rat models that can be used in parallel for target validation, drug screening, and predictive toxicology. The company is providing animal models and services related to therapeutic proof-of-concept and predictive toxicology to help pharma clients accelerate their product development processes. Over time, PhysioGenix expects to provide these services in concert with internal early drug development programs.